Page 61 - Read Online

Page 22 of 23 Koukourakis et al. J Cancer Metastasis Treat 2022;8:38 https://dx.doi.org/10.20517/2394-4722.2022.43

immediate surgery in resectable pancreatic cancer: results of the first prospective randomized phase II trial. Strahlenther Onkol
2015;191:7-16. DOI PubMed PMC
94. Luo J. KRAS mutation in pancreatic cancer. Semin Oncol 2021;48:10-8. DOI PubMed PMC
95. Troiani T, Martinelli E, Capasso A, et al. Targeting EGFR in pancreatic cancer treatment. Curr Drug Targets 2012;13:802-10. DOI
PubMed
96. Mutgan AC, Besikcioglu HE, Wang S, Friess H, Ceyhan GO, Demir IE. Insulin/IGF-driven cancer cell-stroma crosstalk as a novel
therapeutic target in pancreatic cancer. Mol Cancer 2018;17:66. DOI PubMed PMC
97. Annese T, Tamma R, Ruggieri S, Ribatti D. Angiogenesis in pancreatic cancer: pre-clinical and clinical studies. Cancers (Basel)
2019;11:381. DOI PubMed PMC
98. Hosein AN, Brekken RA, Maitra A. Pancreatic cancer stroma: an update on therapeutic targeting strategies. Nat Rev Gastroenterol
Hepatol 2020;17:487-505. DOI PubMed PMC
99. Crowley F, Park W, O’Reilly EM. Targeting DNA damage repair pathways in pancreas cancer. Cancer Metastasis Rev 2021;40:891-
908. DOI PubMed PMC
100. Stephen AG, Esposito D, Bagni RK, McCormick F. Dragging ras back in the ring. Cancer Cell 2014;25:272-81. DOI PubMed
101. Infante JR, Somer BG, Park JO, et al. A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in
combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas. Eur J Cancer 2014;50:2072-81.
DOI PubMed
102. Zhu X, Cao Y, Liu W, et al. Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy
plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial.
Lancet Oncol 2022;23:e105-15. DOI PubMed
103. Forster T, Huettner FJ, Springfeld C, et al. Cetuximab in pancreatic cancer therapy: a systematic review and meta-analysis. Oncology
2020;98:53-60. DOI PubMed
104. Maurel J, Sánchez-Cabús S, Laquente B, et al. Outcomes after neoadjuvant treatment with gemcitabine and erlotinib followed by
gemcitabine-erlotinib and radiotherapy for resectable pancreatic cancer (GEMCAD 10-03 trial). Cancer Chemother Pharmacol
2018;82:935-43. DOI PubMed
105. Abdel-Wahab R, Varadhachary GR, Bhosale PR, et al. Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-
0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma. J Hematol Oncol
2018;11:71. DOI PubMed PMC
106. Sahai V, Saif MW, Kalyan A, et al. A phase I/II open-label multicenter single-arm study of FABLOx (Metronomic 5-fluorouracil
Plus. nab ;5:35-42. DOI PubMed PMC
107. Cascinu S, Berardi R, Sobrero A, et al. Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: a
GISCAD randomized phase II study. Dig Liver Dis 2014;46:182-6. DOI PubMed PMC
108. Reni M, Cereda S, Milella M, et al. Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma: a phase II
randomised trial. Eur J Cancer 2013;49:3609-15. DOI PubMed
109. Ioka T, Okusaka T, Ohkawa S, et al. Efficacy and safety of axitinib in combination with gemcitabine in advanced pancreatic cancer:
subgroup analyses by region, including Japan, from the global randomized Phase III trial. Jpn J Clin Oncol 2015;45:439-48. DOI
PubMed PMC
110. Falcomatà C, Bärthel S, Widholz SA, et al. Selective multi-kinase inhibition sensitizes mesenchymal pancreatic cancer to immune
checkpoint blockade by remodeling the tumor microenvironment. Nat Cancer 2022;3:318-36. DOI PubMed PMC
111. Ko AH, LoConte N, Tempero MA, et al. A phase I Study of FOLFIRINOX plus IPI-926, a hedgehog pathway inhibitor, for advanced
pancreatic adenocarcinoma. Pancreas 2016;45:370-5. DOI PubMed PMC
112. Van Cutsem E, Tempero MA, Sigal D, et al. Randomized phase III Trial of pegvorhyaluronidase Alfa with nab-paclitaxel plus
gemcitabine for patients with hyaluronan-high metastatic pancreatic adenocarcinoma. J Clin Oncol 2020;38:3185-94. DOI PubMed
PMC
113. Ramanathan RK, McDonough SL, Philip PA, et al. Phase IB/II randomized study of FOLFIRINOX plus pegylated recombinant
human hyaluronidase versus FOLFIRINOX Alone in patients with metastatic pancreatic adenocarcinoma: SWOG S1313. J Clin
Oncol 2019;37:1062-9. DOI PubMed PMC
114. Rubinson D, Wolpin BM, Warsofsky IS, et al. Durable clinical benefit from PARP inhibition in a platinum-sensitive, BRCA2-
mutated pancreatic cancer patient after earlier progression on placebo treatment on the POLO trial: a case report. J Gastrointest Oncol
2021;12:3133-40. DOI PubMed PMC
115. Kindler HL, Hammel P, Reni M, et al. Overall survival results from the POLO trial: a phase iii study of active maintenance olaparib
versus placebo for germline BRCA-mutated metastatic pancreatic cancer. J Clin Oncol 2022:JCO2101604. DOI PubMed
116. Murphy JE, Wo JY, Ryan DP, et al. Total neoadjuvant therapy with FOLFIRINOX in Combination with losartan followed by
chemoradiotherapy for locally advanced pancreatic cancer: a phase 2 clinical trial. JAMA Oncol 2019;5:1020-7. DOI PubMed PMC
117. Chen Z, Zhang N, Chu HY, et al. Connective tissue growth factor: from molecular understandings to drug discovery. Front Cell Dev
Biol 2020;8:593269. DOI PubMed PMC
118. Carrieri FA, Smack C, Siddiqui I, Kleinberg LR, Tran PT. Tumor treating fields: at the crossroads between physics and biology for
cancer treatment. Front Oncol 2020;10:575992. DOI PubMed PMC
119. Henriksen A, Dyhl-Polk A, Chen I, Nielsen D. Checkpoint inhibitors in pancreatic cancer. Cancer Treat Rev 2019;78:17-30. DOI